Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
03/2005
03/31/2005WO2005027854A2 T cell regulatory genes associated with immune disease
03/31/2005WO2005027853A2 Method for treating snoring and sleep apnea with leukotriene antagonists
03/31/2005WO2005027852A2 Compositions of polyacids and polyethers and methods for their use in reducing pain
03/31/2005WO2005027851A2 Treatment of severe distal colitis
03/31/2005WO2005027850A2 Treating or preventing restless legs syndrome using prodrugs of gaba analogs
03/31/2005WO2005027849A2 Rouge free pharmaceutical water for injection (wfi) water system
03/31/2005WO2005027848A2 Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators
03/31/2005WO2005027847A2 Antibodies for use against sars
03/31/2005WO2005027846A2 Elicitation of antibodies to self peptides in mice by immunization with dendritic cells
03/31/2005WO2005027845A2 Method of identifying cell surface molecules involved in cancer metastasis
03/31/2005WO2005027844A2 Dna vaccine compositions and methods of use
03/31/2005WO2005027843A2 Chronotherapeutic dosage forms
03/31/2005WO2005027842A2 Combinations of drugs for the treatment of neoplasms
03/31/2005WO2005027841A2 Cells, compositions and methods for repressing b cell autoantibody secretion and for treating autoimmune disease
03/31/2005WO2005027840A2 Combination approaches for generating immune responses
03/31/2005WO2005027838A2 Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives
03/31/2005WO2005027837A2 Substituted sulfonamides
03/31/2005WO2005027836A2 Immunogen
03/31/2005WO2005027835A2 Therapeutic immunization of hiv-infected individuals
03/31/2005WO2005027833A2 Compound and method for treating androgen-independent prostate cancer
03/31/2005WO2005027832A2 Edta containing compositions and uses thereof
03/31/2005WO2005027830A2 Chimeric transcription factor decoy oligonucleotides
03/31/2005WO2005027828A2 Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
03/31/2005WO2005027827A2 Host defense factor x (hdfx)
03/31/2005WO2005027826A2 Methods and treating severe acute respiratory syndrome
03/31/2005WO2005027825A2 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
03/31/2005WO2005027823A2 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3)
03/31/2005WO2005027822A2 Stabilized formulations of phosphatidylserine
03/31/2005WO2005027820A2 System and method of aneurism monitoring and treatment
03/31/2005WO2005016283A3 Peptides for enhanced cell attachment and growth
03/31/2005WO2005011600A3 Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals and methods for making and using same
03/31/2005WO2005009355A3 Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
03/31/2005WO2005007102A3 Phytochemicals for the treatment of mastalgia, endometriosis and hpv-related conditions including cervical dysplasia
03/31/2005WO2005002520A3 Ophthalmic compositions for treating ocular hypertension
03/31/2005WO2004112696A3 Methods and compositions for delivery of catecholic butanes for treatment of diseases
03/31/2005WO2004110371A3 Method for the treatment of malignancies
03/31/2005WO2004110338A3 Methods of treating obesity and related disorders using tellurium and selenium compounds
03/31/2005WO2004108092A3 Tannate compositions and methods of use
03/31/2005WO2004108086A3 HYDANTOIN DERIVATIVES AS INHIBITORS OF TUMOR NECROSIS FACTOR-α CONVERTING ENZYME (TACE)
03/31/2005WO2004105688A3 Bactericidal composition and associated method
03/31/2005WO2004105679A3 Use of a nutritional composition for treating hypertension
03/31/2005WO2004103299A8 Compositions and methods for the treatment of cns injuries
03/31/2005WO2004100883A3 Method for preparing thermoformed compositions containing acrylic polymer binders, pharmaceutual dosage forms and methods of preparing the same
03/31/2005WO2004100870A3 Compositions and methods for wt1 specific immunotherapy
03/31/2005WO2004098538A3 Nitrosated and nitrosylated compounds, compositions and methods of use
03/31/2005WO2004098508A3 Methods for production of non-disease causing hemoglobin by ex vivo oligonucleotide gene editing of human stem/progenitor cells
03/31/2005WO2004098496A3 Compounds for the treatment of metabolic disorders
03/31/2005WO2004096154A3 Methods for treating degenerative diseases/injuries
03/31/2005WO2004096140A3 Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
03/31/2005WO2004091553A3 Film forming polymers, methods of use, and devices and applications thereof
03/31/2005WO2004087076A3 Methods for inhibiting adipogenesis and for treating type 2 diabetes
03/31/2005WO2004087062A3 Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
03/31/2005WO2004084838A3 Identification, quantification, and characterization of t cells and t cell antigens
03/31/2005WO2004084824A3 Biaryl substituted 6-membered heterocyles as sodium channel blockers
03/31/2005WO2004075839A3 Methods and compositions for modulating apoptosis
03/31/2005WO2004075838A3 Method and compositions for the treatment of meconium aspiration syndrome
03/31/2005WO2004064748A3 Compositions and methods for treatment of ovarian cancer
03/31/2005WO2004064742A3 Methods and compositions for p2x receptor calcium entry channels and other calcium entry mechanisms
03/31/2005WO2004064734A3 Combination therapies for the treatment of cancer
03/31/2005WO2004064711A3 Modulation of deubiquitinase family members
03/31/2005WO2004041192A3 Panels of molecular targets differentially expressed during cd8+ t-cell priming
03/31/2005WO2004032876A3 Deguelin as a chemopreventive agent for lung cancer
03/31/2005WO2003103605A3 Flexible vaccine assembly and vaccine delivery platform
03/31/2005WO2003099215A3 Antisense modulation of glucocorticoid receptor expression
03/31/2005US20050070608 Pharmaceutical compositions and method of using levodopa and carbidopa
03/31/2005US20050070596 Methods for treatment of inflammatory diseases using CT-3 or analogs thereof
03/31/2005US20050070565 Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
03/31/2005US20050070545 For treatment or prevention of metabolic and cell proliferative diseases; modifying lipid metabolism
03/31/2005US20050070543 Compositions of a chromene or phenyl acetic acid cyclooxygenase-2 selective inhibitor and an ACE inhibitor for the treatment of central nervous system damage
03/31/2005US20050070538 Compounds and uses thereof in modulating amyloid beta
03/31/2005US20050070472 Treatment of pancreatitis with amylin
03/31/2005US20050070470 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
03/31/2005US20050070460 topically administering to the respiratory tract of a patient with infection, an immune response modifier compound in specific dosage to reduce infection by the agent
03/31/2005US20050069896 Rb pathway and chromatin remodeling genes that antagonize let-60 Ras signaling
03/31/2005US20050069608 Mixture of phosphorus and calcium; compressed into tablets; chewing candy substrate
03/31/2005US20050069561 vaccine against Newcastle Disease contains one or more mutant immunogens of the NDW strain that lack the antigenic binding site on the F glycoprotein which is recognized by the monoclonal antibody mAb 54.
03/31/2005US20050069555 Vaccine adjuvants; hepatitis c virus; modulation immunology response
03/31/2005US20050069541 Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
03/31/2005US20050069499 Mixture of corticosteroid, propellant and carrier
03/31/2005CA2544874A1 Rouge free pharmaceutical water for injection (wfi) water system
03/31/2005CA2539270A1 Immunogen
03/31/2005CA2539182A1 Chronotherapeutic dosage forms
03/31/2005CA2539021A1 Combination approaches for generating immune responses
03/31/2005CA2538991A1 Treatment of severe distal colitis
03/31/2005CA2538857A1 Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives
03/31/2005CA2538840A1 Dna vaccine compositions and methods of use
03/31/2005CA2538802A1 Treating or preventing restless legs syndrome using prodrugs of gaba analogs
03/31/2005CA2538729A1 Compound and method for treating androgen-independent prostate cancer
03/31/2005CA2538570A1 Combinations of drugs for the treatment of neoplasms
03/31/2005CA2538381A1 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3)
03/31/2005CA2538291A1 Substituted sulfonamides
03/31/2005CA2535645A1 Therapeutic immunization of hiv-infected individuals
03/31/2005CA2532831A1 Host defense factor x (hdfx)
03/31/2005CA2523657A1 Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
03/30/2005EP1517909A2 Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
03/30/2005EP1517710A1 Pegylated factor vii glycoforms
03/30/2005EP1517679A1 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
03/30/2005EP1390025B1 Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders
03/30/2005EP1235831B1 New oxabispidine compounds useful in the treatment of cardiac arrhythmias
03/30/2005EP1194140B1 Pharmaceutical composition containing fenofibrate and preparation method
1 ... 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 ... 295